Edwards Lifesciences Corporation NYSE EW issued its quarterly earnings data on Tuesday The medical research company reported 0 84 EPS for the quarter missing the Zacks consensus estimate of 0 86 by 0 02 RTT News reports The business had revenue of 821 50 million during the quarter compared to analyst estimates of 833 85 million Edwards Lifesciences Corporation had a net margin of 22 16 and a return on equity of 27 17 Edwards Lifesciences Corporation s revenue was up 11 1 on a year over year basis During the same period in the previous year the company posted 0 68 earnings per share Edwards Lifesciences Corporation updated its Q4 guidance to 0 84 0 94 EPS Edwards Lifesciences Corporation NYSE EW traded up 0 12 on Tuesday reaching 114 25 2 326 660 shares of the company traded hands The firm has a 50 day moving average price of 111 17 and a 200 day moving average price of 112 34 The stock has a market capitalization of 24 12 billion a price to earnings ratio of 34 65 and a beta of 0 62 Edwards Lifesciences Corporation has a 52 week low of 81 12 and a 52 week high of 121 45 In related news CEO Michael A Mussallem sold 32 900 shares of the business s stock in a transaction that occurred on Monday July 31st The stock was sold at an average price of 114 80 for a total value of 3 776 920 00 The transaction was disclosed in a document filed with the Securities Exchange Commission which can be accessed through the SEC website Also VP Catherine M Szyman sold 4 681 shares of the business s stock in a transaction that occurred on Monday July 31st The stock was sold at an average price of 115 78 for a total value of 541 966 18 The disclosure for this sale can be found here In the last three months insiders sold 201 161 shares of company stock valued at 22 826 072 2 13 of the stock is currently owned by company insiders A number of brokerages recently commented on EW Canaccord Genuity reissued a buy rating and issued a 150 00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday June 28th Cowen and Company reaffirmed a buy rating and set a 135 00 price target on shares of Edwards Lifesciences Corporation in a research note on Thursday October 12th BidaskClub cut shares of Edwards Lifesciences Corporation from a buy rating to a hold rating in a research note on Friday August 25th Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a strong buy rating to a hold rating in a research note on Monday July 17th Finally Bank of America Corporation raised their price target on shares of Edwards Lifesciences Corporation from 140 00 to 150 00 and gave the stock a buy rating in a research note on Thursday July 27th Seven equities research analysts have rated the stock with a hold rating fifteen have assigned a buy rating and one has issued a strong buy rating to the company s stock Edwards Lifesciences Corporation presently has an average rating of Buy and an average price target of 120 75 TRADEMARK VIOLATION WARNING Edwards Lifesciences Corporation EW Issues Earnings Results Misses Expectations By 0 02 EPS was first published by Week Herald and is the property of of Week Herald If you are accessing this article on another domain it was illegally copied and republished in violation of United States international copyright and trademark legislation The correct version of this article can be read at https weekherald com 2017 10 24 edwards lifesciences corporation ew issues earnings results misses expectations by 0 02 eps html Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient s diseased or defective heart valve The Company is engaged in patient focused innovations for structural heart disease and critical care monitoring Its segments include United States Europe Japan and Rest of World Receive News Ratings for Edwards Lifesciences Corporation Daily Enter your email address below to receive a concise daily summary of the latest news and analysts ratings for Edwards Lifesciences Corporation and related companies with MarketBeat com s FREE daily email newsletter